MEDOVEX CORP. (NASDAQ:MDVX) Files An 8-K Entry into a Material Definitive Agreement
ITEM 1.01

On June 24, 2019, Medovex Corp. (“the Company”) filed a press release to its shareholders (the “Press Release”). A copy of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information. Exhibit 99.1, which is incorporated herein by reference.

(d) Exhibits

The exhibits listed below are furnished as Exhibits to this Current Report on Form 8-K.

Medovex Corp. Exhibit
EX-99.1 2 ex99-1.htm   Medovex’s Transition to H-CYTE Underscores Biotechnology Focus   Announces Long-Term Agreement to Launch a Promising New Cellular Treatment for COPD   ALPHARETTA,…
To view the full exhibit click here